The U.S. pharmaceutical industry wants a piece of China’s market of 1.4 billion people, but weaknesses in that country’s intellectual property laws present a challenge. The good news: The republic has strengthened some patent laws. The bad news: Some observers see the changes as little more than window dressing.
Hurdle Removed: One bright spot is a 2018 law that applies to generic drugmakers not based in China. Drugmakers no longer have to repeat efficacy and safety studies in China if they already completed the research in another country.
Scales Tilted: Other new laws contain loopholes designed to benefit Chinese companies. ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.